

# BCCA Protocol Summary for Treatment of Hairy Cell Leukemia with Cladribine

**Protocol Code:**  
**Tumour Group:**  
**Contact Physician:**

LYCDA  
 Lymphoma  
 Dr. Laurie Sehn

**ELIGIBILITY:**

- All patients with Hairy Cell Leukemia

**TESTS:**

- Baseline: CBC & diff, creatinine, HBsAg, HBcoreAb

**PREMEDICATIONS:**

- None

**TREATMENT:**

Drug	Dose	BCCA Administration Guideline
Cladribine	0.14 mg/kg/day	IV in 500 mL NS over 2 hours daily for 5 days
<b>OR</b>		
	0.14 mg/kg/day	SC daily for 5 days

Cladribine is usually given only once. There is no dose reduction for hematologic blood counts for this first cycle. If repeated, it should be given after recovery of blood counts to baseline following the dose reductions below.

**DOSE MODIFICATIONS:**

**1. Hematologic:**

ANC (x 10 <sup>9</sup> /L)*		Platelets (x 10 <sup>9</sup> /L)*	Dose
less than 1.2	OR	less than 100	Delay until count recovery

**2. Renal Dysfunction:** For any patient with a serum creatinine above normal and for all patients above the age of 60 years, a creatinine clearance should be measured or calculated using the following formula:

Estimated creatinine clearance (in mL/minute) =

For men:  $[1.23 \times (140 - \text{age in y}) (\text{weight in kg})] \div \text{serum creatinine in micromol/L}$

For women:  $[1.04 \times (140 - \text{age in y}) (\text{weight in kg})] \div \text{serum creatinine in micromol/L}$

Creatinine Clearance (mL/min)	Dose	Actual Dose and Schedule (Note change in number of days)
greater than 70	100%	0.14 mg/kg/day x 5 days
30 – 70	60%	0.14 mg/kg/day x 3 days
less than 30	DO NOT USE	

## PRECAUTIONS:

1. **Neutropenia:** fever or other evidence of infection must be assessed promptly and treated aggressively.
2. **Hepatitis B Reactivation:** All lymphoma patients should be tested for both HBsAg and HBcoreAb. If either test is positive, such patients should be treated with Lamivudine 100 mg/day orally, for the entire duration of chemotherapy and for six months afterwards. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to halting chemotherapy.

**Call Dr. Laurie Sehn or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.**

Date activated: 01 May 1993

Date last revised: 01 Feb 2011 (change contact physician)

## References:

1. Cheson B. Purine analogues. J Clin Oncol 1992;10:352-5.
2. Piro LD, Carrera CJ, Carson DA and Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl J Med 1990;322:1117-21.